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During the past 5 decades, an increasing percentage of the population has attained geriatric status. Advances in medical technology, surgical procedures, medical practice, and drug development have added to the length and quality of life. The elderly population has a higher prevalence of chronic and multiple diseases. Therefore, physicians often must treat patients with multiple chronic diseases such as cardiovascular diseases, arthritis, diabetes, dementia, hypertension, and cancers. In the richest economies, medical advances have been accompanied by increased health care spending for the elderly population; these costs are increasing proportionally faster than the elderly segment of the population. Drug therapy is used widely for all age groups, but in elderly persons, the risk is greater for an adverse drug reaction. The occurrence and effect of adverse drug reactions can be reduced by an increase in physician knowledge and awareness of this problem. [1] [2] [3] [4] An adverse drug reaction is a noxious or unwanted response that occurs with a dose that usually would be therapeutic. If the response to a usual dose is excessive, it is termed idiosyncratic. If the observed signs and symptoms are an unexpected response of the immune system, the
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Physicians will treat larger numbers of elderly patients as the US population ages. Being treated simultaneously for more than 1 condition with multiple prescription drugs is only 1 reason why elderly patients are at greater risk of experiencing adverse drug reactions. The need for physicians to minimize the incidence of these reactions has become incumbent on both physicians and administrators. We review the underlying reasons why the elderly population is at risk of adverse drug reactions and summarize the response is termed hypersensitivity. A drug-drug interaction can occur when 2 or more drugs are used but usually has no demonstrable adverse consequence. However, a notable portion of adverse drug reactions result from drug interactions in which the effects of one or more drugs become augmented or diminished beyond the limits of the required therapeutic window. [4] [5] [6] [7] The increased frequency of adverse drug reactions has become a focus of clinical pharmacology. The etiology of unwanted drug effects has involved examination of drug pharmacokinetics (specifically, the time course of drug absorption, distribution, metabolism, and excretion) and pharmacodynamics (especially the clinical aspects of altered physiological responses to drug action including diminished compensatory homeostatic response in elderly persons). Bleeding due to oral anticoagulants, hypoglycemia from diabetes treatment, and gastropathy associated with nonsteroidal anti-inflammatory drugs have been identified in epidemiological studies as frequent adverse drug reactions in elderly persons. 8, 9 Because polypharmacy is common, the potential for adverse drug reactions has increased for every drug class. [10] [11] [12] Adverse drug reactions in the elderly population are usually not idiosyncratic; they are more likely extensions of the usual effects of the drug. Such reactions are responsible for both hospital admissions and prolonged hospital stays. These adverse drug effects can be reduced and perhaps prevented by the physician anticipating the effects of drug toxicity and understanding how the patient's age and health status will likely affect drug dosing. 13 To understand how drug handling is altered for elderly patients, we discuss the effects of aging on drug pharmacokinetics (absorption, distribution, and elimination). Next we consider issues of pharmacodynamic change that result from altered sensitivity and modified response to a given stimulus, and how decreased homeostatic mechanisms contribute to altered response. We suggest ways to help elderly persons avoid adverse drug reaction and summarize the underlying mechanisms of adverse drug reactions in these patients.
PHARMACOKINETIC PARAMETERS OF DRUG ABSORPTION, DISTRIBUTION, AND ELIMINATION Drug Absorption
Most drug absorption is via the gastrointestinal tract after oral ingestion. Elderly persons may have decreased gastrointestinal motility and gastrointestinal blood flow and increased gastric pH. These age-related changes would be expected to decrease gastrointestinal drug absorption; however, decreased intestinal motility results in a longer time for drug absorption, which explains why drug absorption is quantitatively unaffected by aging. Consequently, in clinical practice, when rapid achievement of a therapeutic concentration is important (such as with antibiotic use), alternative routes of administration should be considered for elderly patients. Obviously, gastrointestinal diseases can impede drug absorption. 10, 14 Little information exists on the absorption of delayedrelease formulations in elderly patients or on the absorption of transdermal, transbuccal, or transbronchial drug administrations in this group.
Drug Distribution
The volume of distribution (V D ) is not an actual physiological measurement but is an important pharmacokinetic measurement. 15 Volume of distribution is defined as the amount of drug in the body divided by the concentration of drug in the blood or plasma per kilogram of body weight. A value for V D greater than the volume of blood or plasma would suggest that a drug has partitioned into or has become bound to tissue components. The V D is important in drug therapies that require loading doses (eg, digoxin, procainamide, and amiodarone). Calculations of loading doses are based on the desired steady-state blood level and the V D :
Lean body mass and body water decrease with age, resulting in decreased V D . Drugs that distribute into muscle (digoxin) or into body water (aminoglycosides) will attain a higher initial plasma concentration after administration as a result of decreases in their V D . Many commonly used drugs, such as procainamide, quinidine, propranolol, atenolol, sotalol, theophylline, hydrochlorothiazide, various antibiotics, and several sedative-hypnotics, are watersoluble. Water-soluble drugs are distributed less effectively in elderly patients with decreased muscle mass and body water. This situation can be magnified by the presence of cardiovascular disease, which further compromises blood flow to organs.
The increase in adipose tissue in elderly persons increases the V D of lipophilic drugs because fat acts as a depot for these agents, which include amiodarone, desipramine, diazepam, haloperidol, and digitoxin. [15] [16] [17] It has been postulated that the effects of ethanol are increased in elderly persons, especially women, because of reduced V D (decreased body water), causing a higher blood concentration of ethanol for any quantity of ethanol consumed. 18 The potency and duration of action of certain drugs are increased as both liver size and hepatic blood flow decrease along with subsequent hepatic inactivation. Renal function is decreased similarly, resulting in higher plasma levels of free drug. The characteristic changes observed in elderly persons are further exacerbated in patients with congestive heart failure. 3, 7, [19] [20] [21] [22] Many drugs used in therapy bind to plasma proteins in varying degrees. Free drug concentrations determine pharmacological effect because bound drug cannot bind to target tissues but instead can serve as a drug reservoir. Basic drugs are bound by α1-acid glycoprotein, but this binding is not altered with aging. Most drugs are acidic and are bound by serum albumin; total serum albumin and therefore drug-binding capacity decrease approximately 12% in elderly people. A substantial increase in the fraction of free drug can occur if a drug is displaced from plasma albumin by a second drug. The conditions necessary for a notable drug-drug interaction are (1) the drug is highly bound to plasma albumin (>85%); (2) the free drug has a narrow concentration range between the therapeutic and toxic concentrations; and (3) the drug has a small V D . A classic example of toxicity from drug displacement is the interaction between warfarin (99% bound to albumin; mean ± SD V D , 0.14±0.06 L/kg) and acetylsalicylic acid. Displacement as small as 1% to 2% of bound warfarin doubles or triples the concentration of active plasma anticoagulant, resulting in bleeding.
Diseases common in elderly people can depress albumin. These include some chronic debilitating diseases that require drug therapy, such as heart failure, renal disease, rheumatoid arthritis, hepatic cirrhosis, and some malignancies. Elderly persons require reduced doses of narcotics to achieve analgesia without unwanted depressant effects; the probable cause of this is discussed in the section, "Renal Excretion of Drugs in the Elderly Population." Decreased protein binding is believed to contribute to the need to adjust doses for elderly patients. Studies on intravenous 0.693 × V D Clearance meperidine plasma concentration in control and surgical patient groups found that older patients had higher unbound (free) drug fractions. Similarly, the binding capacity of warfarin was found to decrease proportionally to the lower plasma albumin levels found in the elderly population. Other highly protein-bound drugs include phenytoin, diazepam, chloramphenicol, indomethacin, and furosemide. [23] [24] [25] The greater the binding of a drug to albumin, the more likely the total plasma level will be depressed in elderly persons because of their decreased levels of plasma albumin. This situation occurs with use of drugs that bind extensively to albumin, such as warfarin, propranolol, quinidine, phenytoin, and chlorpropamide. Despite drug binding decreasing with age, the unbound fraction increased by 50% with only a few drugs (diflunisal, naproxen, salicylate, valproic acid). 24 Analytical laboratory reports of depressed total plasma levels do not necessarily mean that the concentration of the unbound drug is therapeutically ineffective. Renal disease is characterized by decreased plasma albumin and frequent acidosis, both of which decrease drug binding. 26 
Drug Elimination
The duration and magnitude of both therapeutic and adverse effects of drugs relate to the level of drug in the blood; thus, the processes that eliminate drugs from the blood become important considerations. Knowing that a specific amount of a drug has undergone biotransformation or has been removed physically by filtration into the urine is not enough information to understand the importance of this action or predict its outcome. This is better expressed by 2 pharmacological concepts, clearance and half-life, which are important to understanding adverse drug reactions in the elderly population.
Drug Clearance.-Clearance is the measure of fractional loss of drug per unit time. The unit of clearance, milliliters per minute per kilogram, is derived from the ratio of drug elimination by all routes (amount/time) and the concentration of the drug (amount/volume), normalized by being expressed per kilogram of lean body weight. Stated in another way, clearance is the amount of blood flow completely extracted of drug per unit time. It represents the efficiency of drug extraction from blood. Clearance does not indicate how much drug is being removed, but rather the volume of plasma that would need to be completely freed of drug to account for the elimination of the drug.
For example, an individual with a renal plasma flow of 700 mL/min and a drug extraction of 25% has a renal clearance of 175 mL/min. Clearance values typically are expressed as per kilogram of body weight to facilitate comparison between individuals. The greater the clearance, the more rapidly a drug is removed from blood or plasma.
Total body clearance is the sum of the drug clearances by all organs. The 2 major sites of drug clearance are the liver and kidneys; other sites such as the lung and gastrointestinal tract play lesser roles. [1] [2] [3] 7, 8 In the treatment of diseases with drugs, maintaining an effective plasma-drug concentration in the steady state (C ss ) over time is often necessary. The C ss is achievable using a range of clinical drug doses. The systems of drug elimination are generally not saturated; therefore, the absolute rate of drug elimination is essentially a linear function of the plasma concentration of the drug. For most drugs, a constant fraction of the drug in plasma is eliminated per unit time. This is called a first-order process. If elimination systems become saturated, as may occur with ethanol excess, the elimination kinetics become zero-order, wherein a constant quantity of ethanol is eliminated per unit time by the liver microsomal system.
Half-life.-After drug distribution has occurred, the half-life of a drug is the time it takes for the drug concentration in plasma to decrease by 50%. The clinically relevant half-life of a drug is a function of both its V D and clearance; thus, a change in either of these parameters will alter halflife. Half-life (t 1/ 2 ) is described by the relationship:
Although time spent in the absorption phase is a factor, a clinical rule of thumb for attaining better than 90% of C ss is that approximately 4 doses are needed, administered once every half-life of the drug; 4 half-lives are needed to remove 90% of the drug from the body. Therefore, the halflife provides information necessary to determine dosing intervals or the time necessary for stabilization or reduction in effects of the drug related to drug concentrations. 8, 27 The elimination half-life of drugs increases with age. This may be due to decreases in drug clearance or increases in distribution. The half-lives of the following drugs have been found to increase in elderly persons: digoxin, chlorpropamide, quinidine, diazepam, propranolol, erythromycin, nifedipine, ampicillin, prazosin, aspirin, lisinopril, ranitidine, enalapril, and lithium. In summary, the half-life of a drug determines the dosing interval; the volume of distribution determines the loading dose of a drug; and the clearance of a drug determines the dose of drug that must be administered per unit time.
Hepatic Drug Metabolism.-Biotransforming enzymes evolved long before the first instance of intentional medication. These enzymes limit the toxicity of xenobiotic molecules ingested via inadvertent inhalation or inclusion Half-life (h)
in a varied diet. Active constituents of herbal and pharmaceutical medicines are inactivated or directed toward elimination via a range of hepatic metabolic reactions depending primarily on inherent functional groups and the structure of the molecule. Phase I reactions transform functional groups of the parent molecule (oxidations, reductions, and hydrolytic reactions) (see subsequent discussion of P-450 enzymes). Most of these reactions inactivate or detoxify a bioactive molecule by making it unrecognizable or unavailable to the biotarget (cellular or nuclear receptor, mitochondrial or cytoplasmic enzyme or protein). Occasionally, the activity of a particular molecule is enhanced by biotransformation; the resulting molecule is described as the active agent or drug, and the parent is considered a prodrug. Phase II reactions (usually coupling the drug with acetate, glycine, glucuronic acid, or sulfate group) are conjugation reactions. The range of capacity between individuals is greater than changes reported to occur in individuals as they age. Most phase II reactions make compounds that are more water-soluble and increase excretion into the urine or bile. However, methylation reactions are an exception to this general rule. 28, 29 For a drug to undergo substantial first-pass metabolism by the liver, it must be efficiently extracted from the blood. Examples of these drugs include narcotic analgesics, propranolol, verapamil, tricyclic antidepressants, theophylline, and numerous antipsychotic agents. Such drugs are extremely dependent on hepatic blood flow, which is decreased 12% to 40% in the elderly population. At some concentration, the ability of the liver to extract and metabolize a drug will be surpassed (saturation of first-pass flowlimited kinetics). When this occurs, a proportionately small increase in total drug dose will result in a large increase in systemic drug concentration as the kinetics become dosedependent. Increased systemic bioavailability has been shown for several highly extracted drugs in elderly persons, such as propranolol, labetalol, and verapamil. Conversely, decreased rates of gastrointestinal absorption may reduce bioavailability of highly extracted drugs because a greater fraction of the drug is metabolized in the first pass through the liver. For such drugs, clearance approaches hepatic blood flow at high extraction ratios (≥0.7), but the duration of action may be prolonged because of slow absorption and/or release from depots or because in situ, a long-lived drug is derived from a short-lived prodrug. Human studies point to changes in drug clearance in elderly persons being derived primarily from the combination of decreased blood flow and liver size. 8, 19, [30] [31] [32] Drugs such as warfarin, phenytoin, and nonsteroidal anti-inflammatory drugs have low hepatic clearance (≤0.3), are substantially bound to plasma proteins with limited free-drug concentrations, and have relatively little firstpass metabolism.
Some drugs shown to have decreased metabolism in elderly persons are listed in Tables 1  33-39 and 2. 40 Literature studies are often difficult to compare because of confounding variables established for specific drugs that are not controlled for in all studies. These include chronic diseases, diet, environmental influences, sex, the use of other drugs, and large variation of individual responses. 2, 19, 31, 32 Biotransformation of drugs in the elderly population is more likely to be the basis of an adverse drug reaction when the hepatic P-450 family of enzymes is involved. In the normal healthy population, 6-fold differences in rates of cytochrome P-450 (CYP) drug metabolism are observed. The large range of normal activity makes it a daunting task to establish causal relationships for adverse drug reactions in an individual; the situation is further complicated because multiple reactions may be possible for a given drug involving CYP enzymes, and many drugs are known to be inducers of selective CYP enzymes that may or may not be involved in their own metabolism. Thus, in theory, even with a drug that a patient has tolerated well, the potential exists for an adverse drug reaction after a second drug that alters the hepatic metabolism is added or discontinued.
For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. Most of the evidence that phase I drug metabolism is decreased in elderly persons is based on rat studies. Seemingly disparate results have been reported in numerous studies of age-related changes in hepatic drug-metabolizing enzymes carried out in human liver biopsy specimens. These studies have failed to show a correlation between sex, age, and drug-metabolizing enzyme activity in the liver. 41, 42 Although there is considerable controversy about the effect of aging on drug metabolism, most studies support an age-related decline in phase I drug metabolism in elderly persons. Studies of drug metabolism in the elderly population have found that decrements in phase I metabolism are selective. Decreased phase I metabolism was found in elderly persons taking imipramine, amitriptyline, and thioridazine, but the metabolic decrement did not encompass all drugs. Phase II, the conjugation pathway, is unchanged in the elderly population.
All structurally related members of a drug class behave the same. Benzodiazepine derivates such as chlordiazepoxide, diazepam, and prazepam are sedative-hypnotic agents that have prolonged elimination times in elderly persons; the drugs are subject to both phase I (oxidative) and phase II (conjugative) metabolism. Elimination of sedative-hypnotics such as oxazepam, lorazepam, and temazepam, drugs subject to only phase II metabolism, is unaltered in elderly persons.
Many drugs are available as the racemic mixture of the naturally occurring dextrorotatory (+) and levorotatory (-) enantiomers (rotary isomers). The variation in pharmacological potency of the 2 enantiomers is termed stereoselectivity. Metabolism also can be stereoselective. Data about total clearance of racemic drug reflect the net clearances for the more and less potent isomers. Recent evidence suggests that aging may result in stereoselective effects on drug clearance that can be dependent on sex. Selective inhibition of clearance of the more potent isomer with aging would lead to greater amounts of more active drug at the same total plasma concentration in elderly patients. The clinical importance of the hypothesized process could be an increase in drug activity obtained at usual therapeutic plasma concentrations of a racemic drug in elderly patients. Hexobarbital enantiomers were cleared by elderly patients at half the rate of younger patients for the (-) enantiomer, whereas the (+) enantiomer was not influenced by age. Other factors may be important in predicting differences in the clearance rates of enantiomers. Young men who took mephobarbitol had faster clearance rates than did young women; also, sex-based differences were observed in elderly patients taking the (-) enantiomer who had slower clearance rates than did younger patients. 43, 44 Although these concepts are scientifically valid and some evidence exists for agerelated changes in stereoselective drug elimination, the clinical importance has yet to be well-defined.
The CYP enzymes, a superfamily of heme proteins, are found in all living species and are involved in metabolism of a wide variety of chemically diverse endogenous and exogenous compounds, including drugs, environmental chemicals, and other xenobiotics. Approximately 1000 CYP enzymes are known, but only 50 are functionally active in humans. These cytochromes are categorized by their amino acid sequences; sequences greater than 40% identical are considered in the same family and are identified by an Arabic numeral. Within the family, amino acid sequences greater than 55% identical are considered in the same subfamily and are identified by a letter. Different individual isoforms in the subfamily are identified by Arabic numerals. Thus, individual CYP enzymes are designated as CYP + family numeral + subfamily letter + individual isoform of subfamily numeral (eg, CYP2D6).
Approximately 8 to 10 isoforms in the CYP1, CYP2, and CYP3 families are involved in most drug metabolism in humans. Individual CYP isoforms have a characteristic substrate specificity based on structural features. However, it is not unusual to have considerable overlaps or for 2 or more CYP isoforms and other drugs that metabolize enzymes to be involved in the metabolism of a drug. 8 Because the genes coding for CYP enzymes and uridine diphosphate glucuronosyltransferases are not associated with the X chromosome, no association would be expected between a person's sex and how well he or she metabolizes drugs. However, some sex-dependent differences in the activity of these enzymes have been documented. Understanding the importance of these differences may be complicated by the lack of controls for age or ethnicity. CYP3A4 activity is higher in women, whereas CYP2C9, CYP1A2, CYP2E1, and uridine diphosphate glucuronosyltransferase activity may be higher in men. CYP2D6 may be slightly higher in white women; however, in other ethnic population studies, CYP2D6 activity was not sex-dependent. CYP2C19 activity has been found to be higher in men, but the studies are not definitive. 45 A simple summary of hepatic drug metabolism is that in general, drug dosage of hepatically metabolized drugs should be reduced in elderly patients because decreases in hepatic clearance can be anticipated, but the exact extent of reduction cannot be precisely quantified.
Induction and Inhibition of Drug Metabolism.-An increased synthesis of CYP protein occurs in the liver with exposure to certain drugs, chemicals, and environmental pollutants. The enzyme induction results in an increased rate of biotransformation of drug and decreased availability of the parent drug. For drugs that are metabolized to reactive compounds (activated), induction may be associated with increased activity and/or toxicity. Some drugs can induce both the biotransformation of other compounds and their own metabolism (autoinduction).
Inducing drugs are usually specific to a particular CYP family. Widely diverse chemicals may induce the same set of drug-metabolizing enzymes. For example, glucocorticoids and anticonvulsants induce CYP3A4, whereas acetone, isoniazid, and long-term use of ethanol induce CYP2E1. 45, 46 Inhibition of drug biotransformation enzymes results in increased levels of the parent drug, prolonged pharmacological effects, and an increased incidence of drug toxicity. Competition for the active site of CYP enzymes by 2 or more drugs can result in a decrease in the metabolism (activation or inactivation) of 1 of these drugs. The drug interaction effect depends on the concentration of each drug and on the affinity of each drug for the enzyme. Inhibition of CYP2D6 by quinidine is a clinically notable example of competitive inhibition. Cimetidine and ketoconazole inhibit oxidative drug metabolism by forming a tight complex with the heme iron of CYP. In macrolide antibiotics such as erythromycin and troleandomycin, a metabolite of these compounds is the heme-binding species. The irreversible interaction of CYP enzymes and a suicide inactivator result in the destruction of heme. Secobarbital and synthetic steroids such as norethindrone and ethinyl estradiol are examples of suicide inactivators. Some of these relationships are shown in Table 3 . 47 A common mechanism of inhibition for some phase II enzymes is the depletion of necessary cofactors.
Grapefruit juice, taken proximally to the administration of selected drugs, increases serum levels of numerous drugs known to be metabolized by CYP3A4. The bioavailability of many CYP3A4 substrates has been found to increase when these substrates are taken with grapefruit juice. In most studies, the area under the curve was increased 1.5-to 3-fold, but 7-to 15-fold increases have been reported. The grapefruit-drug interaction results mainly from a reduction of first-pass metabolism in the small intestine. It has been reported that grapefruit juice selectively decreases CYP3A4 in the small intestine, where the enzyme is extensively expressed. Numerous drugs have had reports of increased bioavailability due to grapefruit juice, including felodipine, nifedipine, nisoldipine, nitrendipine, triazolam, midazolam, lovastatin, and simvastatin. 48 Drug augmentation of enzyme induction can increase drug clearance and lower the effect of a given drug dose. A drug-induced increase of drug-metabolizing enzymes may be reduced in elderly persons. 49 However, enzyme induction by smoking is unchanged in the elderly population. 50 Increased doses of a drug are required for a pharmacological effect if a drug is simultaneously used with a second drug that induces inactivation of the first drug. A decrease in drug dose should be considered when an inducing drug is withdrawn because the therapeutic drug dose used may become an overdose.
Genetic Polymorphism.-Large individual differences in drug biotransformation exist in human populations. These differences in the ability of individuals to metabolize a drug through a specific pathway are in part genetically determined. Phenotypic differences in the quantity of drug cleared through a polymorphically controlled pathway led to a classification of individuals as rapid or slow metabolizers. Drug interactions may result in a rapid metabolizer appearing to be a slow metabolizer. Major deficiencies in drug-metabolizing activity are inherited as autosomal recessive traits. blacks in the United States, 60% to 70% in northern Europeans, and 5% to 10% in persons of Asian descent. The most common genetic polymorphisms associated with oxidative drug metabolism are the debrisoquine and mephenytoin polymorphisms. A deficiency in debrisoquine hydroxylase activity in a subset of the population reflects one or more mutations in the CYP2D6 gene, which lead to CYP2D6 proteins that are either absent or have decreased enzyme activity. Individuals can be phenotyped for CYP2D6 metabolism status by administration of a single dose of debrisoquine and measurement of the urinary ratio of unchanged drug to 4-hydroxydebrisoquine. Large-scale CYP2D6 phenotyping studies indicate a 5% to 10% incidence of the slow metabolizer phenotype in whites and about a 1% incidence in Asians. In 95% of the population, the CYP2D6 phenotype can be correctly predicted from a single blood sample using genotyping procedures. 51, 52 A growing number of cardiovascular agents, psychoactive agents, and morphine derivatives are now recognized as CYP2D6 substrates. Impaired metabolism of encainide, flecainide, metoprolol, and phenelzine in slow metabolizers of debrisoquine is associated with an increased incidence of adverse effects. Associations between an extensive metabolizer CYP2D6 phenotype and the incidence of lung and bladder cancers remain controversial. A genetic polymorphism also has been described for the stereoselective hydroxylation of S-mephenytoin at the 4′ position. Poor metabolizers of S-mephenytoin 4′-hydroxylation constitute 3% to 5% of the white population and 20% of Asians. Omeprazole and other proton pump inhibitors are substrates for this CYP enzyme. 7, 19, [52] [53] [54] In general, age-related decreases in liver mass, hepatic enzyme activity, and hepatic blood flow result in a decrease in the overall metabolic capacity of the liver in the elderly For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings.
population. Decreases in the hepatic biotransformation of drugs with a high hepatic extraction ratio in elderly persons are predicted from the decrease in liver blood flow, although the large degree of individual variability in agerelated and disease-related changes in organ function makes generalizations difficult. However, it is noteworthy that age-related decreases in hepatic biotransformation are associated principally with the CYP monooxygenase system, whereas alternate metabolic pathways do not appear to be markedly affected by age. Clinical reports of decreased oxidation of estrogens and benzodiazepines in women relative to men suggest that sex-dependent variations in drug biotransformations also may be important in the pharmacological and toxic responses to certain drugs. At this time, generalizations about such sex-specific differences in drug metabolism are premature. 8, 28 Hepatic Disease.-Any impairment of normal liver function potentially will alter hepatic biotransformation. A disproportionate number of elderly patients have liver disease associated with excess alcohol use, gallstones, cholangitis, gallstone-induced pancreatitis, biliary cirrhosis, and fatty livers associated with diabetes or obesity. Adverse drug reactions may suggest liver dysfunction. The degree to which CYP monooxygenase activity and hepatic elimination are decreased is a function of the severity of liver damage. A decreased hepatic biotransformation of tolbutamide, diazepam, and morphine in patients with hepatic dysfunction has been associated with exaggerated pharmacological responses. Decreases in hepatic blood flow resulting from cardiac insufficiency or β-adrenergic blockade also can affect the rate of hepatic biotransformation. The metabolism of drugs with a high hepatic extraction ratio is limited by liver blood flow. For such drugs, a decreased hepatic blood flow results in decreased rates of biotransformation and clearance of the parent drug and therefore a prolonged effect. Examples of drugs with high extraction ratios whose elimination likely is altered by changes in liver blood flow are lidocaine, propranolol, verapamil, and amitriptyline. 19, 31, 53 Renal Excretion of Drugs in the Elderly Population.-Renal blood flow decreases in elderly persons, even in the absence of overt nephropathy. Renal blood flow is reduced by approximately 1% per year after age 50 years. 55 Many drugs, active and inactive, are excreted by the kidneys. A reduction of renal function can affect the elimination of a drug if it is more than 60% excreted by the kidneys. Higher blood levels of drugs whose elimination is primarily renal are found when the glomerular filtration rate decreases. This may result in accumulation of drugs producing higher drug levels for prolonged periods of time. Some drugs excreted primarily by the kidneys include atenolol, sotalol, digoxin, lithium, amphotericin, pentamidine, procainamide, cimetidine, allopurinol, chlorpropamide, and many antibiotics.
The assessment of renal function in elderly persons may not be quantified accurately by the serum creatinine level alone. Because creatinine formation is a function of muscle mass, a normal serum creatinine level may be seen when the reduction in creatinine clearance or glomerular filtration is substantial. Differences in creatinine clearance correlate with an approximate 2-fold increase in the half-life of penicillin in the elderly patient. 56 Similarly, decreases in digoxin clearance occur in the elderly patient compared with the younger patient (mean ± SD clearance): 83±17 mL/min per 1.73 m 2 vs 53±9 mL/min per 1.73 m 2 .
57
Consistent findings in the elderly population are a decline in renal function, decreased renal blood flow, decreased renal mass, and decreased creatinine clearance (Table 4 ). Algorithms to estimate creatinine clearance based on an individual's age, sex, and serum creatinine levels can provide accurate estimates of the glomerular filtration rate and have widespread clinical applications when renal failure is not an issue. The effect of age can be shown by examining the most commonly used formula for estimating creatinine clearance: 
58-60
When renal dysfunction is suspected, creatinine clearance is more important than serum creatinine and the algorithm. For drugs excreted by the kidneys that have narrow therapeutic indices, obtaining blood levels may be useful. Drugs such as digoxin, chlorpropamide, indomethacin, metformin, atenolol, methotrexate, procainamide, salicylic acid, and many antibiotics may require dosage adjustments in elderly patients because of decreased renal function. Phase II drug metabolism reactions, such as conjugation, usually inactivate drugs. However, studies have shown that a conjugated metabolite of morphine, morphine-6-glucuronide, is 40 times more potent than morphine. 61 Approximately 80% of the analgesic action of the opiate derives from morphine-6-glucuronide after a single dose of morphine, and possibly even more at steady state. The use of morphine in patients with impaired renal function results in prolonged effects and toxicity because of the accumulation of morphine-6-glucuronide. 62, 63 The central nervous system depressant effects of opiates, including respiratory depression, are especially dangerous in elderly persons who are more sensitive to the drugs. Meperidine is oxidatively demethylated in the liver to the still-active norFor personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. meperidine, which is renally eliminated. Both renal disease and/or decreased renal function in the elderly population can produce excess drug effects with meperidine.
PHARMACODYNAMICS: ALTERED DRUG RESPONSE OBSERVED IN THE ELDERLY POPULATION Drug Sensitivity
If drug sensitivity denotes intrinsic abnormal responses to usual drug doses, sensitivity is unusual and difficult to document in the elderly population. Because of the changes in renal drug elimination, hepatic drug clearance, pharmacodynamics, and homeostatic mechanisms in elderly persons, discerning the role of intrinsic sensitivity is difficult.
Elderly patients have lower dose requirements for warfarin anticoagulation; their increased sensitivity to warfarin is due to a greater decrease in clotting factor synthesis. 39, 64 Elderly patients are more sensitive to sedative-hypnotics, as confirmed by several clinical pharmacological studies. 65, 66 Studies on analgesic drug use in elderly patients have shown decreased narcotic requirements. Postoperative pain relief was obtained with lesser doses of intramuscular narcotics in elderly patients compared with younger ones. To establish differences in sensitivity to narcotics in elderly persons, pharmacokinetic and pharmacodynamic parameters have been measured simultaneously. Pharmacokinetic studies of narcotics have shown reduced clearance in elderly patients. Electroencephalographic quantification of narcotic effects on the brain over time with simultaneous measurements of serum narcotic concentrations have shown increased brain sensitivity to narcotics in elderly patients.
67-69

Pharmacodynamic Changes
As people age, responses to certain stimulant agents change. 70, 71 The functioning of their autonomic nervous systems changes, a suggested basis for orthostatic hypotension. Elderly patients have decreased variation of heart rate in the course of β-adrenergic blockade, indicating a decrease of parasympathetic function. 72, 73 Although parasympathetic response is reduced in the elderly population, plasma norepinephrine and blood pressure levels are increased, indicating an increase of cardiac sympathetic activity. 70 The elderly population also has decreased baroreceptor function. 71 Drug sensitivity in elderly patients has been shown to be reduced to both isoproterenol stimulation and β-adrenergic blockade. Moreover, exercise, which increases plasma catecholamines, does not reliably increase heart rate in elderly persons. 74 These observations confirm decreased β-adrenergic responses in elderly patients. Cardiac output in healthy normal elderly persons is increased as in normal younger persons, but the physiology is different. Elderly persons increase stroke volume to a greater degree and heart rate to a lesser degree than do young exercising persons. This difference is a consequence of a decreased adrenergic-stimulated response with aging. 71, 72, 75 The arterial system of elderly persons has attenuated responses to both β-adrenergic stimulation and blockade comparable to those of younger persons. 70 
Decreased Homeostatic Mechanisms
The hallmark of the aging process in physiological terms is diminished adaptive capacity. Physiological responses that require integrated activity of several organ systems may result in a slow recovery rate in the older patient after physiological or pathologic displacements. Elderly patients with decreased plasma volume, diminished vasomotor regulation, impaired glucose tolerance, greater morbidity from infections, and other limitations may be more susceptible to adverse effects of drugs. Decreased homeostatic responses may engender adverse drug reactions in elderly persons that might be compensated for in younger patients. Treatment of elderly patients can be extremely complex because of multiple diseases and drug therapies that can produce adverse drug reactions.
For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. Even with careful medical care, elderly patients can experience adverse drug effects. Sedative-hypnotics, antidepressants, antianxiety drugs, and ethanol are less well tolerated by elderly patients, especially when multiple agents are used simultaneously. Disturbed mental function and hallucinations may result from use of sympathomimetic, antiparkinsonian, and/or anticholinergic drugs in the elderly population. In addition, these agents may exacerbate glaucoma or urinary retention. Some apparent suicides in elderly patients may be accidental deaths due to injudicious prescription of sedative drugs or repeated ingestion of prescribed drugs by a confused older patient.
Several pathophysiologic features of the aging process contribute to adverse drug reactions in elderly patients. Moreover, anoxic, ischemic, diabetic, and hypothyroid states increase sensitivity to morphine, barbiturates, and other sedative-hypnotic drugs.
In drug therapy for the elderly patient, it is important to individualize therapy. Unexpected responses such as hypersensitivity, tolerance, and toxicity must be anticipated.
Avoidance of Adverse Drug Reactions in the Elderly Population.-Minimizing or avoiding adverse drug reactions in elderly persons is a rational goal on both personal and socioeconomic levels. Pharmacokinetic and pharmacodynamic limitations in elderly patients who frequently use multiple drugs for several disease entities make them more prone to adverse drug reactions. These reactions can occur at normal therapeutic drug doses and because of drug-drug interactions.
The following considerations in drug therapy for elderly patients can help decrease adverse reactions.
1. Know what you are treating. Establishing a definite diagnosis often permits selection of the proper drug or drugs and a treatment period. Treatment is aimed optimally at changing the natural history of disease (diabetes, hypertension, major depression, coronary artery disease, rheumatoid arthritis), although relief from the pain of arthritides, cancer, etc is an important therapeutic goal. The gain vs risk aspect of drug therapy for the elderly population should be considered in light of their greater propensity for adverse drug effects.
2. The elderly patient's drug regimen should be reviewed frequently. A physician should be alert to the possibility that other consulting physicians may be prescribing the same or other drugs, creating the possibility of drug overdoses or drug-drug interactions. Also, patients may be using over-the-counter drugs, including herbal remedies with properties that influence prescribed drug therapy. Many physicians ask patients to carry an updated card that lists their prescribed and over-the-counter drugs (Table 5   76 ). Elderly patients may have several conditions meriting drug use. The simultaneous use of several drugs may result For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings. in pharmacodynamic augmentation of a drug's unwanted actions (Table 6   77 ). 3. The number of drugs used should be the minimum needed to deal effectively with the problem. The pharmacological actions and the mechanisms of the drug or drug clearance should be reviewed and the patient monitored for both therapeutic and toxic effects of these drugs. The minimal effective dose should be used in elderly persons because clearance mechanisms and homeostatic responses may be compromised.
4. Attributing signs and symptoms associated with aging, such as weakness, confusion, anorexia, anxiety, and memory loss, to old age rather than suspecting the effects of drugs should be avoided. This is especially true if patients are receiving sedative-hypnotic, antidepressant, antianxiety, or anticholinergic drugs.
Although patient noncompliance and confusion may contribute to the adverse effects of multiple drug therapy, there are often pharmacokinetic and sometimes pharmacodynamic reasons for these unwanted effects. Adverse drug effects could be decreased by making elderly patients and/ or their caregivers more aware of drug handling and of potential interactions. Pharmacists should play a key role for both identifying potential interactions and assisting in patient education.
Summary of Mechanisms.-Mechanisms by which drug-drug interactions can occur include (1) inhibition of drug absorption, (2) decreased hepatic blood flow, (3) inhibition of renal excretion, (4) inhibition or stimulation of drug metabolism, (5) displacement from albumin binding, and (6) pharmacodynamic effects of drugs on tissue responses.
Some clinically important drug interactions are listed in Table 7 . Although hospital or pharmacy computer programs are designed to prevent adverse drug interactions, the patient must be queried about prescriptions from other physicians, over-the-counter medications, and herbal or dietary supplements. Web sites provide extended content about specific topics (eg, CYP enzymes), but as always, the physician must use due diligence.
CONCLUSION
The elderly patient merits special consideration before and after drugs are prescribed. To achieve pharmacological treatment without adverse interactions, physicians are assisted by pharmacists and ideally are assisted by patients aware of signs of potential drug-drug interaction and the need for appropriate remediation. Knowledge of the consequences of aging and of why pharmacokinetics may be modified in the elderly population should help the physician avoid adverse drug reactions.
